Combination decongestion therapy in hospitalized heart failure: Loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists

Muthiah Vaduganathan, Robert J. Mentz, Stephen J. Greene, Michele Senni, Naoki Sato, Savina Nodari, Javed Butler, Mihai Gheorghiade*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Congestion is the most common reason for admissions and readmissions for heart failure (HF). The vast majority of hospitalized HF patients appear to respond readily to loop diuretics, but available data suggest that a significant proportion are being discharged with persistent evidence of congestion. Although novel therapies targeting congestion should continue to be developed, currently available agents may be utilized more optimally to facilitate complete decongestion. The combination of loop diuretics, natriuretic doses of mineralocorticoid receptor antagonists and vasopressin antagonists represents a regimen of currently available therapies that affects early and persistent decongestion, while limiting the associated risks of electrolyte disturbances, hemodynamic fluctuations, renal dysfunction and mortality.

Original languageEnglish (US)
Pages (from-to)799-809
Number of pages11
JournalExpert review of cardiovascular therapy
Volume13
Issue number7
DOIs
StatePublished - Jul 1 2015

Keywords

  • Heart failure
  • Vasopressin antagonists
  • loop diuretics
  • mineralocorticoid receptor antagonists
  • neurohormones

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Combination decongestion therapy in hospitalized heart failure: Loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists'. Together they form a unique fingerprint.

Cite this